Skip to main content

Advertisement

SpringerLink
Log in

Raynaud’s phenomenon

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Coffman JD: Raynaud’s Phenomenon. New York: Oxford University Press; 1989. A comprehensive review of the etiology, clinical picture, diagnosis, and treatment of Raynaud’s phenomenon.

    Google Scholar 

  2. Maricq HR, Carpentier PH, Weinrich MC, et al.: Geographic variation in the prevalence of Raynaud’s phenomenon—Charleston, SC, USA vs Tarentaise, Savoie, France. J Rheumatol 1993, 20:70–76. A possible future classic documenting the varying prevalence of Raynaud’s phenomenon according to climate.

    PubMed  CAS  Google Scholar 

  3. Gifford RW Jr, Hines EA Jr: Raynaud’s disease among women and girls. Circulation 1957, 16:1012–1021.

    PubMed  Google Scholar 

  4. Lewis T: Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud’s disease. Heart 1929, 15:7–101.

    Google Scholar 

  5. Coffman JD, Cohen RA: a aa a 2 -Adrenergic and 5-HT2 receptor hypersensitivity in Raynaud’s phenomenon. J Vasc Med Biol 1990, 2:100–105.

    Google Scholar 

  6. Belch JJF, Meilien H: Pharmacotherapy of Raynaud’s phenomenon. Drugs 1996, 52:682–695. A short, good review of Raynaud’s phenomenon and its treatment.

    PubMed  CAS  Google Scholar 

  7. Rodeheffer RJ, Rommer JA, Wigley F, et al.: Controlled double-blind trial of nifedipine in the treatment of Raynaud’s phenomenon. N Engl J Med 1983, 308:880–883. A well-planned and careful study of the value of nifedipine in Raynaud’s phenomenon.

    Article  PubMed  CAS  Google Scholar 

  8. Schmidt JF, Valentin N, Nielsen SL: The clinical effect of felodipine and nifedipine in Raynaud’s phenomenon. Eur J Clin Pharmacol 1989, 37:191–192.

    Article  PubMed  CAS  Google Scholar 

  9. Kallenberg CGM, Wouda AA, Meens L, et al.: Once daily felodipine in patients with primary Raynaud’s phenomenon. Eur J Clin Pharmacol 1991, 40:313–315.

    Article  PubMed  CAS  Google Scholar 

  10. Leppert J, Jonasson T, Nilsson H, et al.: The effect of isradipine, a new calcium-channel antagonist in patients with primary Raynaud’s phenomenon: a single-blind dose-response study. Cardiovasc Drug Ther 1989, 3:397–401.

    Article  CAS  Google Scholar 

  11. DaCosta JT, Gomes JAM, Santo JE, et al.: Inefficacy of diltiazem in the treatment of Raynaud’s phenomenon with associated connective tissue disease: a double blind placebo controlled study. J Rheumatol 1987, 14:858–859.

    CAS  Google Scholar 

  12. Nielsen SL, Vithing K, Rasmussen K: Prazosin treatment of primary Raynaud’s phenomenon. Eur J Clin Pharma-col 1983, 24:421–423. A well-planned study and evaluation of the effect of a 1 -adrenoreceptor blockade in Raynaud’s phenomenon.

    Article  CAS  Google Scholar 

  13. Coffman JD, Cohen AS: Total and capillary blood flow in Raynaud’s phenomenon. N Engl J Med 1971, 285:259–263.

    Article  PubMed  CAS  Google Scholar 

  14. LeRoy EC, Downey JA, Cannon PJ: Skin capillary blood flow in scleroderma. J Clin Invest 1971, 50:930–939.

    PubMed  CAS  Google Scholar 

  15. Franks AG Jr: Topical glyceryl trinitrate as adjunctive treatment in Raynaud’s disease. Lancet 1982, 1:76–77.

    Article  PubMed  Google Scholar 

  16. Johnston ENM, Summerly R, Birnstingl M: Prognosis in Raynaud’s phenomenon after sympathectomy. Br Med J 1965, 1:962–964.

    PubMed  CAS  Google Scholar 

  17. Janoff KA, Phinney ES, Porter JM: Lumbar sympathec-tomy for lower extremity vasospasm. Am J Surg 1985, 150:147–152.

    Article  PubMed  CAS  Google Scholar 

  18. O’Brien BM, Kumar PAV, Mellow CG, Oliver TV: Radical microarteriolysis in the treatment of vasospastic disorders of the hand, especially scleroderma. J Hand Surg [Br] 1992, 17B:447–452.

    Article  Google Scholar 

  19. Jobe JB, Beetham WP, Roberta DE, et al.: Induced vasodilation as a home treatment for Raynaud’s disease. J Rheumatol 1985, 12:953–956. Demonstrates that a simple nondrug treatment may improve Raynaud’s phenomenon in many patients.

    PubMed  CAS  Google Scholar 

  20. Yocum DE, Hoden R, Sundstrom CR, et al.: Use of biofeedback training in treatment of Raynaud’s disease and phenomenon. J Rheumatol 1985, 12:90–93.

    PubMed  CAS  Google Scholar 

  21. Rademaker M, Cooke ED, Almond NE, et al.: Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double blind randomized study. Br Med J 1989, 298:561–564.

    Article  CAS  Google Scholar 

  22. Mohrland JS, Porter JM, Smith EA, et al.: A multicenter, placebo-controlled, double-blind study of prostaglan-din E1 in Raynaud’s syndrome. Ann Rheum Dis 1985, 44:754–760.

    Article  PubMed  CAS  Google Scholar 

  23. Challenor VF: Angiotensin converting enzyme inhibitors in Raynaud’s phenomenon. Drugs 1994, 48:864–867.

    PubMed  CAS  Google Scholar 

  24. Pancera P, Sansone S, Secchi S, et al.: The effects of thromboxane inhibition (picotamide) and angio-tensin II receptor blockade (losartan) in primary Raynaud’s phenomenon. J Intern Med 1997, 242:373–376.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Peripheral Vascular Section, Evans Memorial Department of Clinical Research and Department of Medicine, Boston University Medical Center, One Boston Medical Center Place, 02118, Boston, MA, USA

    Jay D. Coffman MD

Authors
  1. Jay D. Coffman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coffman, J.D. Raynaud’s phenomenon. Curr Treat Options Cardio Med 2, 219–226 (2000). https://doi.org/10.1007/s11936-000-0016-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-000-0016-z

Keywords

Search

Navigation